Fostamatinib disodium | Syk inhibitor

CAS:1025687-58-4

Catalog Number:10-4144

Fostamatinib disodium (1025687-58-4) is a prodrug of the spleen tyrosine kinase inhibitor (Syk) R406 and is approved 

for the treatment of chronic immune thrombocytopenia.  It has demonstrated significant reduction in inflammatory 

mediators such as TNFα, IL-1, IL-6, and IL-8 in arthritis models.1  Syk IC50 = 41 nM – Fostamatinib also inhibits Flt3, Lyn, 

and Lck with similar potency in vitro but displays higher selectivity Syk in cellular assays.2 Significantly inhibits LPS-

induced inflammatory response via blocking STAT1/3 signaling.3 Fostamatinib restored myeloid homeostasis in s

evere COVID-19.4 Displayed synergistic effects with anti-PDL1 therapy against neuroblastoma.5 Fostamatinib induces 

metabolic reprogramming of acute myeloid leukemia stem cells.6

CAS:1025687-58-4

Catalog Number:10-4144

Activity:Syk inhibitor

Chemical Names:[6-[[5-Fluoro-2-(3,4,5-trimethoxyanilino)pyrimidin-4-yl]amino]-2,2-dimethyl-3-oxopyrido

[3,2-b][1,4]oxazin-4-yl]methyl phosphate Disodium salt

Alternate Name:R788

Molecular Weight:624.43

Molecular Formula:C23H24FN6O9P·2Na

Solubility:Soluble in DMSO (12 mg/ml with warming)

Physical Properties:White solid

Purity:>98% HPLC

NMR: (Conforms)

Storage Temperature:-20°C

Stability:Stable for up to 2 years when stored as supplied @ -20°C. Solutions in DMSO may be stored at -20°C for up to 3 months.

Shipping Code:RT

Safety Data Sheet:Download Safety Data Sheet

Product Data Sheet:Download Product Data Sheet

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary 

applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur 

a $20 restocking/refund fee

References/Citations:

Bajpai et al. (2009), Fostamatinib, a Syk inhibitor prodrug for the treatment of inflammatory diseases; iDrug 12 174

McAdoo and Tam (2011), Fostamatinib Disodium; Drugs Future 36 273

Guo et al. (2024), Fostamatinib, a Spleen Tyrosine Kinase Inhibitor, Exerts Anti-Inflammatory Activity via Inhibiting STAT1/3 

Signaling Pathways; J. Inflamm. Res. 17 9757

Wigerblad et al. (2023), Spleen tyrosine kinase inhibition restores myeloid homeostasis in COVID-19; Sci. Adv. 9 eade8272

Rohila et al. (2023), Targeting macrophage Syk enhances responses to immune checkpoint blockade and radiotherapy in high-

risk neuroblastoma; Front. Immunol. 14 1148317

Polak et al. (2020), SYK inhibition targets acute myeloid leukemia stem cells by blocking their oxidative metabolism; Cell Death Dis. 11 956